Abstract #3934

Multiparametric MRI as a biomarker of response to neoadjuvant second-generation hormone therapy for localized prostate cancer- a pilot study

Fiona Fennessy^1,2, Andriy Fedorov¹, Mark Vangel³, Robert Mulkern⁴, Rosina Lis⁵, Maria Tretiakova⁶, Clare Tempany¹, and Mary Ellen Taplin⁷

¹Radiology, Brigham and Women's Hospital, Boston, MA, United States, ²Dana Farber Cancer Institute, Boston, MA, United States, ³Radiology, Massachusetts General Hospital, Boston, MA, United States, ⁴Radiology, Children's Hospital Boston, Boston, MA, United States, ⁵Pathology, Dana Farber Cancer Institute, Boston, MA, United States, ⁶Pathology, University of Washington, Seattle, WA, United States, ⁷Oncology, Dana Farber Cancer Institute, Boston, MA, United States

Advanced prostate cancer (PCa) is driven by androgen receptor (AR) signaling, and as such the AR is an important therapeutic target to prevent PCa progression. The aim of this pilot study was to explore a role for prostate multiparametric MRI (mpMRI) as a biomarker for treatment response of localized prostate cancer to neoadjuvant treatment with the second-generation AR inhibitor enzalutamide. We demonstrate that quantitative mpMRI may play an important role as a biomarker of response to neoadjuvant treatment of localized PCa, and MRI-based tumor volumetrics may act as a surrogate for RCB at prostatectomy. These findings are worthy of investigation in a larger clinical setting.

This abstract and the presentation materials are available to members only; a login is required.

Join Here